인간 안티트롬빈 시장 : 시장 규모, 점유율, 성장률, 산업 분석, 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of human antithrombin Market

The global human antithrombin market was valued at USD 381.32 million in 2025 and is projected to grow from USD 396.34 million in 2026 to USD 566.36 million by 2034, registering a CAGR of 4.56% during the forecast period (2026-2034). In 2025, Europe dominated the market with a 43.17% share, supported by strong plasma fractionation infrastructure and the presence of leading manufacturers.

Human antithrombin is a plasma-derived glycoprotein that plays a vital role in regulating blood coagulation by inactivating thrombin and other serine proteases. It is widely used for preventing abnormal blood clotting, particularly in patients with hereditary antithrombin deficiency and in high-risk surgical or critical care settings.

Market Overview

Human antithrombin concentrates are essential in managing coagulation disorders, especially in patients undergoing complex surgical procedures or those suffering from thrombophilia and disseminated intravascular coagulation (DIC). The growing prevalence of cardiovascular diseases, increasing organ transplant procedures, and rising use of extracorporeal membrane oxygenation (ECMO) are key factors contributing to market expansion.

Major companies operating in this market include CSL, Octapharma AG, Grifols, S.A., Kedrion S.p.A., and Takeda Pharmaceutical Company Limited. Their strong presence in plasma-derived medicinal products strengthens overall market growth.

Market Dynamics

Market Drivers

Increasing Usage for Therapeutic Applications

The primary growth driver is the expanding therapeutic application of human antithrombin. The rising number of cardiac surgeries, organ transplants, and critically ill patients requiring anticoagulant therapy is increasing demand. According to a June 2024 article published in Annals of Thoracic Surgery Short Reports, the annual average cardiac surgery volume in the U.S. reached 271.5 procedures per 100,000 population.

Hereditary antithrombin deficiency affects approximately 0.02% to 0.05% of the global population, creating sustained demand for lifelong supplementation therapy. Surgeons and ICU physicians increasingly depend on fast-acting antithrombin formulations, supporting market growth from USD 396.34 million in 2026 to USD 566.36 million by 2034.

Market Restraints

Safety Concerns and Side Effects

Despite widespread therapeutic use, plasma-derived antithrombin concentrates carry certain risks. These include allergic reactions, anaphylaxis, bleeding complications, and thromboembolic events. There is also a minimal risk of transmission of unknown infectious agents, despite rigorous safety measures. In cases of severe sepsis, high-dose antithrombin III combined with heparin may increase hemorrhage risk. These factors limit adoption in certain clinical scenarios.

Market Opportunities

Expansion into Combination Therapies

Growing research on combination therapies is creating new opportunities. Studies indicate that combining antithrombin with heparin produces synergistic anticoagulant effects. Healthcare professionals are increasingly exploring such combinations to enhance therapeutic outcomes. The expansion of applications beyond hereditary deficiency, particularly in sepsis and DIC management, is expected to provide long-term growth opportunities.

Market Challenges

Complex Regulatory and Reimbursement Frameworks

Strict regulatory requirements for plasma-derived products slow product approvals and commercialization timelines. Additionally, reimbursement disparities across countries limit accessibility, especially in low- and middle-income nations. These challenges can restrain market penetration despite clinical demand.

Market Trends

Expanding Clinical Applications

Antithrombin is increasingly used beyond hereditary deficiency treatment. In Japan, anticoagulation therapy for septic patients with DIC includes antithrombin concentrate as part of standard care. A dose of 1,500 IU/day has been approved within the Japanese healthcare system. Such expanded clinical applications represent a notable market trend.

Segmentation Analysis

By Application

The market is segmented into therapeutic and research & diagnostic applications.

• The therapeutic segment dominated the market in 2024 and continues to lead due to high clinical demand. Antithrombin supplementation is widely used to manage heparin resistance. In December 2024, the American Society of Hematology highlighted antithrombin supplementation as a preferred treatment in such cases.
• The research & diagnostic segment holds a smaller share due to limited product availability.

By Dosage Form

The market is categorized into lyophilized powder and liquid formulations.

• Lyophilized powder held the dominant share in 2024, owing to enhanced stability and ease of storage. Products such as THROMBATE III (Grifols) and Thrombotrol VF (CSL) are available in this form.
• The liquid segment accounts for a smaller share due to limited commercial availability.

By End User

The market includes hospitals & clinics, pharmaceutical & biotechnology companies, and research institutes.

• Hospitals & clinics held the largest share in 2024 due to increased usage in surgical and critical care settings.
• The pharmaceutical and biotechnology segment is expected to grow steadily due to expanding research applications.

Regional Outlook

Europe

Europe led the market with a value of USD 164.62 million in 2025 and a 43.17% market share. Growth is driven by strong plasma manufacturing infrastructure, supportive government initiatives such as "France 2030," and the presence of major players like LFB and Grifols.

Asia Pacific

Asia Pacific is projected to witness the fastest growth due to rising congenital deficiency cases and strategic collaborations. For example, in 2019, SK Pharma partnered with BioPharma Indonesia for plasma production initiatives.

North America

North America holds a comparatively smaller share due to regulatory hurdles limiting product approvals.

Rest of the World

Latin America and the Middle East & Africa are experiencing gradual growth, supported by improving healthcare access.

Competitive Landscape

The market is semi-consolidated, with leading players including CSL, Grifols, Kedrion, and Octapharma AG. These companies maintain strong global distribution networks and plasma-derived product portfolios. Strategic collaborations, facility expansions, and clinical trials are shaping the competitive environment.

Conclusion

The global human antithrombin market is expected to grow steadily from USD 381.32 million in 2025 to USD 566.36 million by 2034, driven by rising surgical procedures, increasing cases of hereditary deficiency, and expanding therapeutic applications. While safety concerns and regulatory complexities present challenges, ongoing research, combination therapies, and strong European leadership are likely to sustain long-term market expansion. As healthcare systems continue to prioritize advanced anticoagulation management, human antithrombin will remain a critical component in treating complex coagulation disorders worldwide.

Segmentation By Application

• Therapeutic
• Research & Diagnostic

By Dosage Form

• Lyophilized Powder
• Liquid

By End User

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Industry
• Research Institutes

By Region

• North America (By Application, Dosage Form, End User, and Country/Sub-Region)
  • U.S.
  • Canada
• Europe (By Application, Dosage Form, End User, and Country/Sub-Region)
  • Germany
  • France
  • U.K.
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Application, Dosage Form, End User, and Country/Sub-Region)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Southeast Asia
  • Rest of the Asia Pacific
• Rest of the World (By Application, Dosage Form, and End User)

Table of Content

1. Introduction

• 1.1. Market Scope
• 1.2. Market Segmentation
• 1.3. Market Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Cardiovascolar Diseases, By Key Countries
• 4.2. Regolatory Scenario, By Key Countries
• 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Approvals, Launches etc.)

5. Global Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Application
  • 5.1.1. Therapeutic
  • 5.1.2. Research & Diagnostic
• 5.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 5.2.1. Lyophilized Powder
  • 5.2.2. Liquid
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Hospitals & Clinics
  • 5.3.2. Pharmaceutical & Biotechnology Industry
  • 5.3.3. Research Institutes
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Rest of the World

6. North America Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Application
  • 6.1.1. Therapeutic
  • 6.1.2. Research & Diagnostic
• 6.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 6.2.1. Lyophilized Powder
  • 6.2.2. Liquid
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Hospitals & Clinics
  • 6.3.2. Pharmaceutical & Biotechnology Industry
  • 6.3.3. Research Institutes
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Application
  • 7.1.1. Therapeutic
  • 7.1.2. Research & Diagnostic
• 7.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 7.2.1. Lyophilized Powder
  • 7.2.2. Liquid
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Hospitals & Clinics
  • 7.3.2. Pharmaceutical & Biotechnology Industry
  • 7.3.3. Research Institutes
• 7.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.4.1. Germany
  • 7.4.2. UK
  • 7.4.3. France
  • 7.4.4. Italy
  • 7.4.5. Spain
  • 7.4.6. Scandinavia
  • 7.4.7. Rest of Europe

8. Asia Pacific Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Application
  • 8.1.1. Therapeutic
  • 8.1.2. Research & Diagnostic
• 8.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 8.2.1. Lyophilized Powder
  • 8.2.2. Liquid
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Hospitals & Clinics
  • 8.3.2. Pharmaceutical & Biotechnology Industry
  • 8.3.3. Research Institutes
• 8.4. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. South Korea
  • 8.4.6. Southeast Asia
  • 8.4.7. Rest of Asia Pacific

9. Rest of World Human Antithrombin Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Application
  • 9.1.1. Therapeutic
  • 9.1.2. Research & Diagnostic
• 9.2. Market Analysis, Insights and Forecast - By Dosage Form
  • 9.2.1. Lyophilized Powder
  • 9.2.2. Liquid
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Hospitals & Clinics
  • 9.3.2. Pharmaceutical & Biotechnology Industry
  • 9.3.3. Research Institutes

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. CSL
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. Financials (Based on Availability)
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. SWOT,Etc.
  • 10.2.2. Octapharma AG
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. Financials (Based on Availability)
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. SWOT,Etc.
  • 10.2.3. Takeda Pharmaceutical Company Limited
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. Financials (Based on Availability)
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. SWOT,Etc.
  • 10.2.4. Grifols, S.A.
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. Financials (Based on Availability)
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. SWOT,Etc.
  • 10.2.5. Medix Biochemica
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. Financials (Based on Availability)
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. SWOT,Etc.
  • 10.2.6. Kedrion S.p.A.
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. Financials (Based on Availability)
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. SWOT,Etc.
  • 10.2.7. Scripps Laboratories
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. Financials (Based on Availability)
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. SWOT,Etc.